Biotest AG (BIO)

Overview

Biotest Aktiengesellschaft is a prominent biopharmaceutical company with a focus on developing, manufacturing, and marketing biological medicines on both a national and international scale. Originally established in 1946 and headquartered in Dreieich, Germany, the company has evolved from Biotest Serum-Institut GmbH to its current form in 1986. Biotest Aktiengesellschaft operates under the umbrella of Grifols, S.A., a global healthcare giant, indicating a strong backing and strategic alignment in the biopharmaceutical domain. With operations segmented into Therapy, Plasma & Services, and Other, Biotest is at the forefront of advancing treatments in hematology, clinical immunology, and intensive care medicine. Its comprehensive portfolio addresses several critical areas, including hemophilia, hepatitis B, immune deficiencies, and other significant conditions requiring acute therapy and prophylaxis.

Products and Services

• Haemoctin and Vihuma: Designed for hemophilia A, these products are used both for acute therapy and as prophylaxis measures.
• Haemonine: A solution for hemophilia B, offering acute therapy and preventative care.
• Cytotect CP Biotest: Specially formulated for combating cytomegalovirus infections, ensuring patient safety and recovery.
• Fovepta: This vaccine is crucial for hepatitis B prophylaxis in newborns, offering a shield against the virus from the earliest moments of life.
• Hepatect: Used for the prophylaxis of hepatitis B reinfection, this product is a cornerstone in the management of hepatitis B.
• Intratect and Yimmugo: These are essential in treating primary immune and secondary antibody deficiency syndromes, as well as certain autoimmune diseases and neurological conditions.
• Varitect: Targeting varicella zoster virus infections, this product is pivotal in treating such conditions effectively.
• Zutectra: A key product for hepatitis B re-infection prophylaxis after liver transplantation, ensuring the liver's health and patient's well-being.
• Albiomin and Biseko: These products play a crucial role in restoring and maintaining circulating blood volume, vital for patient recovery in various medical situations.
• Cofact: Designed for the treatment of clotting factors deficiency, providing essential support in blood clotting disorders.
• Fibrinogen: A specific treatment for congenital fibrinogen deficiency, crucial for patients with this rare condition.
• Trimodulin: Targeting community-acquired pneumonia and COVID-19, this product is part of Biotest’s response to global pandemics and respiratory diseases.
• Pentaglobin: An integral solution for treating bacterial infections, showcasing Biotest's commitment to addressing acute and severe infections.